OBJECTIVE: To discover whether Inflammatory Neuropathy Cause and Treatment Group (INCAT) electrophysiological criteria for demyelinating neuropathy predict response to immunotherapy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: This was a retrospective case note study of patients who had attended Guy's Hospital Peripheral Nerve Clinic between January 2001 and March 2004, been diagnosed as having CIDP, and given treatment with corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange (PE). Patients' nerve conduction studies (NCS) were reviewed for evidence of demyelination and whether the abnormalities fulfilled modified INCAT electrophysiological criteria. Patients whose NCS fulfilled the criteria were assigned to the neurophysiologically definite CIDP group, while those that did not were labelled as neurophysiologically probable CIDP. Responses to any of the three immunotherapy agents were compared between the two groups. RESULTS: Out of 50 patients, 27 (54%) were classified as neurophysiologically definite and 23 (46%) as neurophysiologically probable CIDP patients. Twenty (74%) neurophysiologically definite and 17 (73.9%) neurophysiologically probable CIDP patients responded to treatment. CONCLUSIONS: INCAT electrophysiological criteria did not predict a higher rate of response to immunotherapy. Neurophysiologically probable CIDP patients should be given a trial of immunotherapy.
OBJECTIVE: To discover whether Inflammatory Neuropathy Cause and Treatment Group (INCAT) electrophysiological criteria for demyelinating neuropathy predict response to immunotherapy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: This was a retrospective case note study of patients who had attended Guy's Hospital Peripheral Nerve Clinic between January 2001 and March 2004, been diagnosed as having CIDP, and given treatment with corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange (PE). Patients' nerve conduction studies (NCS) were reviewed for evidence of demyelination and whether the abnormalities fulfilled modified INCAT electrophysiological criteria. Patients whose NCS fulfilled the criteria were assigned to the neurophysiologically definite CIDP group, while those that did not were labelled as neurophysiologically probable CIDP. Responses to any of the three immunotherapy agents were compared between the two groups. RESULTS: Out of 50 patients, 27 (54%) were classified as neurophysiologically definite and 23 (46%) as neurophysiologically probable CIDPpatients. Twenty (74%) neurophysiologically definite and 17 (73.9%) neurophysiologically probable CIDPpatients responded to treatment. CONCLUSIONS: INCAT electrophysiological criteria did not predict a higher rate of response to immunotherapy. Neurophysiologically probable CIDPpatients should be given a trial of immunotherapy.
Authors: R Hughes; S Bensa; H Willison; P Van den Bergh; G Comi; I Illa; E Nobile-Orazio; P van Doorn; M Dalakas; M Bojar; A Swan Journal: Ann Neurol Date: 2001-08 Impact factor: 10.422
Authors: I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn Journal: J Neurol Neurosurg Psychiatry Date: 2002-05 Impact factor: 10.154
Authors: Alon Abraham; Majed Alabdali; Mohammad Qrimli; Hana Albulaihe; Ari Breiner; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril Journal: PLoS One Date: 2015-10-13 Impact factor: 3.240
Authors: Todd D Levine; Jonathan S Katz; Richard Barohn; Leslie J Vaughan; Mazen M Dimachkie; David S Saperstein; Tahseen Mozaffar; Gil I Wolfe; Matthew S Mayo; Gary J Badger; Lara Katzin; Elissa Ritt; Michelle Greer; Joseph DiStefano; Patrick M Schmidt Journal: Neurol Clin Pract Date: 2018-10